Meeting Banner
Abstract #0370

Relaxation-compensated CEST imaging of the APT can predict response to radiotherapy and progression-free survival in patients with glioma at 3T

Nikolaus von Knebel Doeberitz1, Florian Kroh2,3, Svenja Graß1, Laila König4, Cora Bauspieß1, Philip S. Boyd2, Jürgen Debus4,5,6, Peter Bachert2,3, Mark E. Ladd2,3,6, Heinz-Peter Schlemmer1,6, Andreas Korzowski2, and Daniel Paech1,7
1Division of Radiology, German Cancer Research Center, Heidelberg, Germany, 2Division of Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany, 3Faculty of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany, 4Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, 5Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany, 6Faculty of Medicine, University of Heidelberg, Heidelberg, Germany, 7Department of Neuroradiology, Bonn University Hospital, Bonn, Germany

Synopsis

Keywords: Tumors (Pre-Treatment), CEST & MT, Asymmetry-based and Lorentzian-fit-based CEST contrast reconstruction

Motivation: There is a scarcity of studies comparing the clinical value of asymmetry- and different Lorentzian-fit-based CEST contrasts of the amide proton transfer (APT) and semi-solid magnetization transfer (ssMT) in patients with glioma.

Goal(s): To assess and compare the potential of asymmetry-based (APTwasym) and Lorentzian-fit-based CEST imaging with (MTRRexAPT and MTRRexMT) and without (MTconst) relaxation compensation for the prediction of therapy response and survival in patients with glioma.

Approach: 78 study participants prospectively underwent CEST MRI at baseline before radiotherapy.

Results: Imaging of the MTRRexAPT and MTRRexMT predicted response to radiotherapy, whilst the MTRRexAPT was also associated with progression-free survival.

Impact: Here we demonstrate for the first time that Lorentzian-fit-based CEST imaging of the APT and ssMT with relaxation compensation can predict therapy response and progression-free survival of patients with glioma at baseline before radiotherapy, at 3T.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Abstract

Keywords